Cero Therapeutics Holdings, Inc.
CEROW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $4 in total; no superinvestor holds it.
Other share classesCERO
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cero Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cero Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Francois Eric | Director | – | Apr 21, 2026 | 1 |
| Laporte Kathleen | Director | 965,997Indirect | Jan 9, 2026 | 1 |
| Atwood Brian G | Director | 490,534Indirect | Jan 9, 2026 | 1 |
| Ehrlich Christopher B | Chairman and CEO | 5,791,808 | Jan 9, 2026 | 1 |
| Patel Shami | Director | – | Jan 9, 2026 | 1 |
| Byrnes Michael | Director | – | Jan 9, 2026 | 1 |
| Rolfe Lindsey | Director | – | Jan 9, 2026 | 1 |
| Kucharchuk Andrew Albert | Chief Financial Officer | – | Jan 9, 2026 | 1 |
| Pierce Kristen | Chief Development Officer | – | Jan 9, 2026 | 1 |
| YK Bioventures Opportunities GP I, LLC | 10% Owner | 13,005,169Indirect | Dec 13, 2024 | 0 |
| YK Bioventures Opportunities Fund I, L.P. | 10% Owner | 13,005,169Indirect | Dec 13, 2024 | 0 |
| Kossar Mitchell William | 10% Owner | 13,005,169Indirect | Dec 13, 2024 | 0 |
| Yeung Gary Kahing | 10% Owner | 13,005,169Indirect | Dec 13, 2024 | 0 |
| Sloan Stuart M | 10% Owner | 21,067,956Indirect | Nov 20, 2024 | 0 |
| Carter Charles Ross | Chief Financial Officer | – | Jul 1, 2024 | 0 |
| Rapaport Robyn | Director | – | Mar 27, 2024 | 0 |
| Corey Daniel | Chief Technical Officer | – | Mar 27, 2024 | 0 |
| Phoenix Biotech Sponsor, LLC | 10% Owner | 1,000,000 | Feb 16, 2024 | 0 |
| Geffken Daniel E. | Chief Financial Officer | 10,002 | Feb 16, 2024 | 0 |
| Loewy Caroline M | Director | 5,828 | Feb 16, 2024 | 0 |
| Fisher Douglas | President | 43,300 | Feb 16, 2024 | 0 |
| Kosacz Barbara | Director | 5,828 | Feb 16, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2024 (view filing)6:41 PM ET | Dec 11-13 | 2 days | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −5.96M | $0.0672 | −$400.5K | −31.4%13.0M after | 3 lots |
| Dec 10, 2024 (view filing)8:44 PM ET | Dec 6-10 | 4 days | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −3.66M | $0.1048 | −$383.4K | −16.2%19.0M after | 3 lots |
| Nov 20, 2024 (view filing)4:04 PM ET | Sep 25 | 56 daysLate | Sloan Stuart M10% Owner | SSaleCommon Stock, $0.0001 par value per share | −532.5K | $0.1043 | −$55.5K | −2.5%21.1M after | |
| Nov 14, 2024 (view filing)8:14 PM ET | Oct 10 | 35 daysLate | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −3.25M | $0.10 | −$325.0K | −12.6%22.6M after |